Zika virus encephalitis in immunocompetent mice is dominated by innate immune cells and does not require T or B cells.
Adaptive immunity
Encephalitis
Innate immunity
Microglia
Monocyte
Neutrophil
Type I interferon
Zika virus
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
11 Sep 2019
11 Sep 2019
Historique:
received:
08
02
2019
accepted:
28
08
2019
entrez:
13
9
2019
pubmed:
13
9
2019
medline:
24
3
2020
Statut:
epublish
Résumé
Until the end of the twentieth century, Zika virus (ZIKV) was thought to cause a mostly mild, self-limiting disease in humans. However, as the geographic distribution of ZIKV has shifted, so too has its pathogenicity. Modern-day ZIKV infection is now known to cause encephalitis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome in otherwise healthy adults. Nevertheless, the underlying pathogenetic mechanisms responsible for this shift in virulence remain unclear. Here, we investigated the contribution of the innate versus the adaptive immune response using a new mouse model involving intracranial infection of adult immunocompetent mice with a moderately low dose of ZIKV MR766. To determine the contribution of type I interferons (IFN-Is) and adaptive immune cells, we also studied mice deficient for the IFN-I receptor 1 (Ifnar1 We show that intracranial infection with ZIKV resulted in lethal encephalitis. In wild-type mice, ZIKV remained restricted predominantly to the central nervous system (CNS) and infected neurons, whereas astrocytes and microglia were spared. Histological and molecular analysis revealed prominent activation of resident microglia and infiltrating monocytes that were accompanied by an expression of pro-inflammatory cytokines. The disease was independent of T and B cells. Importantly, unlike peripheral infection, IFN-Is modulated but did not protect from infection and lethal disease. Lack of IFN-I signaling resulted in spread of the virus, generalized inflammatory changes, and accelerated disease onset. Using intracranial infection of immunocompetent wild-type mice with ZIKV, we demonstrate that in contrast to the peripheral immune system, the CNS is susceptible to infection and responds to ZIKV by initiating an antiviral immune response. This response is dominated by resident microglia and infiltrating monocytes and macrophages but does not require T or B cells. Unlike in the periphery, IFN-Is in the CNS cannot prevent the establishment of infection. Our findings show that ZIKV encephalitis in mice is dependent on the innate immune response, and adaptive immune cells play at most a minor role in disease pathogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Until the end of the twentieth century, Zika virus (ZIKV) was thought to cause a mostly mild, self-limiting disease in humans. However, as the geographic distribution of ZIKV has shifted, so too has its pathogenicity. Modern-day ZIKV infection is now known to cause encephalitis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome in otherwise healthy adults. Nevertheless, the underlying pathogenetic mechanisms responsible for this shift in virulence remain unclear.
METHODS
METHODS
Here, we investigated the contribution of the innate versus the adaptive immune response using a new mouse model involving intracranial infection of adult immunocompetent mice with a moderately low dose of ZIKV MR766. To determine the contribution of type I interferons (IFN-Is) and adaptive immune cells, we also studied mice deficient for the IFN-I receptor 1 (Ifnar1
RESULTS
RESULTS
We show that intracranial infection with ZIKV resulted in lethal encephalitis. In wild-type mice, ZIKV remained restricted predominantly to the central nervous system (CNS) and infected neurons, whereas astrocytes and microglia were spared. Histological and molecular analysis revealed prominent activation of resident microglia and infiltrating monocytes that were accompanied by an expression of pro-inflammatory cytokines. The disease was independent of T and B cells. Importantly, unlike peripheral infection, IFN-Is modulated but did not protect from infection and lethal disease. Lack of IFN-I signaling resulted in spread of the virus, generalized inflammatory changes, and accelerated disease onset.
CONCLUSIONS
CONCLUSIONS
Using intracranial infection of immunocompetent wild-type mice with ZIKV, we demonstrate that in contrast to the peripheral immune system, the CNS is susceptible to infection and responds to ZIKV by initiating an antiviral immune response. This response is dominated by resident microglia and infiltrating monocytes and macrophages but does not require T or B cells. Unlike in the periphery, IFN-Is in the CNS cannot prevent the establishment of infection. Our findings show that ZIKV encephalitis in mice is dependent on the innate immune response, and adaptive immune cells play at most a minor role in disease pathogenesis.
Identifiants
pubmed: 31511023
doi: 10.1186/s12974-019-1566-5
pii: 10.1186/s12974-019-1566-5
pmc: PMC6740023
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177Subventions
Organisme : Marie Bashir Institute, University of Sydney (AU)
ID : Seed Funding
Références
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):521-34
pubmed: 12995441
J Immunol. 1952 Aug;69(2):223-34
pubmed: 14946416
Cell. 1992 Mar 6;68(5):869-77
pubmed: 1547488
Methods Mol Med. 2005;116:115-34
pubmed: 16000858
J Neurochem. 2007 Nov;103(3):1019-30
pubmed: 17854352
J Exp Med. 2008 Sep 29;205(10):2319-37
pubmed: 18779347
Viral Immunol. 2008 Dec;21(4):425-33
pubmed: 19115931
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
PLoS Pathog. 2011 Feb;7(2):e1001304
pubmed: 21383977
J Neuroinflammation. 2011 Mar 09;8:23
pubmed: 21388530
J Neurosurg. 2012 Mar;116(3):630-5
pubmed: 22149378
J Virol. 2012 Jun;86(12):6932-46
pubmed: 22496215
Cell Host Microbe. 2012 Oct 18;12(4):544-57
pubmed: 23084921
J Neuroinflammation. 2012 Oct 30;9:246
pubmed: 23111065
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Nat Rev Rheumatol. 2016 Jan;12(1):14-24
pubmed: 26656658
Lancet. 2016 Feb 20;387(10020):719-21
pubmed: 26876373
N Engl J Med. 2016 Dec 15;375(24):2321-2334
pubmed: 26943629
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
N Engl J Med. 2016 Apr 21;374(16):1595-6
pubmed: 26958738
MMWR Morb Mortal Wkly Rep. 2016 Mar 11;65(9):242-7
pubmed: 26963593
Am J Trop Med Hyg. 2016 Jun 1;94(6):1362-1369
pubmed: 27022155
Cell Stem Cell. 2016 May 5;18(5):591-6
pubmed: 27038591
Cell Host Microbe. 2016 May 11;19(5):720-30
pubmed: 27066744
PLoS Negl Trop Dis. 2016 Apr 19;10(4):e0004682
pubmed: 27093158
Cell. 2016 May 19;165(5):1081-1091
pubmed: 27180225
Int J Infect Dis. 2016 Jul;48:85-90
pubmed: 27208633
Nat Rev Microbiol. 2016 Jul;14(7):401
pubmed: 27211788
Cell Host Microbe. 2016 Jun 8;19(6):882-90
pubmed: 27212660
Sci Rep. 2016 Jun 09;6:27670
pubmed: 27279150
DNA Cell Biol. 2016 Aug;35(8):367-72
pubmed: 27348136
Lancet. 2016 Jun 25;387(10038):2599-2600
pubmed: 27353815
Cell. 2016 Aug 25;166(5):1247-1256.e4
pubmed: 27565347
N Engl J Med. 2016 Oct 20;375(16):1598-1601
pubmed: 27579558
J Clin Virol. 2016 Oct;83:63-5
pubmed: 27598870
N Engl J Med. 2016 Oct 20;375(16):1513-1523
pubmed: 27705091
MBio. 2016 Oct 11;7(5):
pubmed: 27729507
EMBO Rep. 2016 Dec;17(12):1766-1775
pubmed: 27797853
Nature. 2016 Dec 15;540(7633):438-442
pubmed: 27798603
PLoS Pathog. 2016 Nov 17;12(11):e1006004
pubmed: 27855206
Cell. 2016 Dec 1;167(6):1511-1524.e10
pubmed: 27884405
Eur Neurol. 2017;77(1-2):45-46
pubmed: 27894121
J Neurosci. 2017 Feb 22;37(8):2161-2175
pubmed: 28123079
Sci Rep. 2017 Jan 27;7:41389
pubmed: 28128342
J Virol. 2017 Mar 29;91(8):
pubmed: 28148798
PLoS Pathog. 2017 Feb 2;13(2):e1006164
pubmed: 28152048
PLoS Pathog. 2017 Feb 23;13(2):e1006184
pubmed: 28231312
J Immunol. 2017 May 1;198(9):3526-3535
pubmed: 28330900
Cell Rep. 2017 Apr 18;19(3):558-568
pubmed: 28423319
PLoS Pathog. 2017 May 25;13(5):e1006378
pubmed: 28542585
Trends Microbiol. 2017 Sep;25(9):701-702
pubmed: 28578821
PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005704
pubmed: 28672028
J Virol. 2017 Oct 27;91(22):
pubmed: 28835502
Nat Commun. 2018 Jan 9;9(1):106
pubmed: 29317641
Front Immunol. 2018 Mar 22;9:593
pubmed: 29623081
Cell Host Microbe. 2018 May 9;23(5):672-685.e6
pubmed: 29746837
Nat Commun. 2018 Aug 7;9(1):3136
pubmed: 30087337
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
J Virol. 1997 Oct;71(10):7832-40
pubmed: 9311871